vs
DELCATH SYSTEMS, INC.（DCTH）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
DELCATH SYSTEMS, INC.的季度营收约是RIVERVIEW BANCORP INC的1.5倍（$20.7M vs $14.0M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -9.1%，领先18.9%），DELCATH SYSTEMS, INC.同比增速更快（37.3% vs 10.4%），DELCATH SYSTEMS, INC.自由现金流更多（$7.7M vs $-736.0K），过去两年DELCATH SYSTEMS, INC.的营收复合增速更高（157.0% vs 24.6%）
德尔卡斯系统公司是一家上市特种医药与医疗器械企业，主打研发经皮灌注技术，该技术可将高剂量化疗药物精准递送至人体特定器官或病变区域。公司总部位于纽约州昆斯伯里，在全球拥有28项专利的知识产权组合，其核心产品经皮肝灌注技术目前正针对肿瘤开展二期和三期临床试验。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
DCTH vs RVSB — 直观对比
营收规模更大
DCTH
是对方的1.5倍
$14.0M
营收增速更快
DCTH
高出26.9%
10.4%
净利率更高
RVSB
高出18.9%
-9.1%
自由现金流更多
DCTH
多$8.4M
$-736.0K
两年增速更快
DCTH
近两年复合增速
24.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $20.7M | $14.0M |
| 净利润 | $-1.9M | $1.4M |
| 毛利率 | 85.5% | — |
| 营业利润率 | -10.5% | 12.4% |
| 净利率 | -9.1% | 9.8% |
| 营收同比 | 37.3% | 10.4% |
| 净利润同比 | 44.2% | 11.8% |
| 每股收益（稀释后） | $-0.05 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DCTHRVSB
| Q4 25 | $20.7M | $14.0M | ||
| Q3 25 | $20.6M | $13.6M | ||
| Q2 25 | $24.2M | $13.3M | ||
| Q1 25 | $19.8M | $12.9M | ||
| Q4 24 | $15.1M | $12.7M | ||
| Q3 24 | $11.2M | $12.8M | ||
| Q2 24 | $7.8M | $12.2M | ||
| Q1 24 | $3.1M | $9.0M |
净利润DCTHRVSB
| Q4 25 | $-1.9M | $1.4M | ||
| Q3 25 | $830.0K | $1.1M | ||
| Q2 25 | $2.7M | $1.2M | ||
| Q1 25 | $1.1M | $1.1M | ||
| Q4 24 | $-3.4M | $1.2M | ||
| Q3 24 | $1.9M | $1.6M | ||
| Q2 24 | $-13.7M | $966.0K | ||
| Q1 24 | $-11.1M | $-3.0M |
毛利率DCTHRVSB
| Q4 25 | 85.5% | — | ||
| Q3 25 | 87.2% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 85.6% | — | ||
| Q4 24 | 85.9% | — | ||
| Q3 24 | 85.4% | — | ||
| Q2 24 | 80.4% | — | ||
| Q1 24 | 71.2% | — |
营业利润率DCTHRVSB
| Q4 25 | -10.5% | 12.4% | ||
| Q3 25 | -1.9% | 10.2% | ||
| Q2 25 | 10.7% | 11.7% | ||
| Q1 25 | 3.2% | 11.3% | ||
| Q4 24 | 20.1% | 12.4% | ||
| Q3 24 | -11.2% | 15.5% | ||
| Q2 24 | -50.4% | 10.0% | ||
| Q1 24 | -327.4% | -47.5% |
净利率DCTHRVSB
| Q4 25 | -9.1% | 9.8% | ||
| Q3 25 | 4.0% | 8.1% | ||
| Q2 25 | 11.2% | 9.2% | ||
| Q1 25 | 5.4% | 8.9% | ||
| Q4 24 | -22.5% | 9.7% | ||
| Q3 24 | 16.6% | 12.2% | ||
| Q2 24 | -176.9% | 7.9% | ||
| Q1 24 | -354.0% | -34.7% |
每股收益（稀释后）DCTHRVSB
| Q4 25 | $-0.05 | $0.07 | ||
| Q3 25 | $0.02 | $0.05 | ||
| Q2 25 | $0.07 | $0.06 | ||
| Q1 25 | $0.03 | $0.05 | ||
| Q4 24 | $-0.06 | $0.06 | ||
| Q3 24 | $0.06 | $0.07 | ||
| Q2 24 | $-0.48 | $0.05 | ||
| Q1 24 | $-0.45 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $43.5M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $111.2M | $164.2M |
| 总资产 | $123.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DCTHRVSB
| Q4 25 | $43.5M | $28.6M | ||
| Q3 25 | $41.8M | $32.8M | ||
| Q2 25 | $34.4M | $34.2M | ||
| Q1 25 | $12.8M | $29.4M | ||
| Q4 24 | $32.4M | $25.3M | ||
| Q3 24 | $8.3M | $31.0M | ||
| Q2 24 | $14.8M | $27.8M | ||
| Q1 24 | $11.8M | $23.6M |
总债务DCTHRVSB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $2.0M | — | ||
| Q2 24 | $4.5M | — | ||
| Q1 24 | $7.4M | — |
股东权益DCTHRVSB
| Q4 25 | $111.2M | $164.2M | ||
| Q3 25 | $114.8M | $163.5M | ||
| Q2 25 | $105.0M | $162.0M | ||
| Q1 25 | $80.2M | $160.0M | ||
| Q4 24 | $68.7M | $158.3M | ||
| Q3 24 | $8.6M | $160.8M | ||
| Q2 24 | $4.2M | $155.9M | ||
| Q1 24 | $14.6M | $155.6M |
总资产DCTHRVSB
| Q4 25 | $123.6M | $1.5B | ||
| Q3 25 | $124.3M | $1.5B | ||
| Q2 25 | $116.9M | $1.5B | ||
| Q1 25 | $87.3M | $1.5B | ||
| Q4 24 | $76.6M | $1.5B | ||
| Q3 24 | $31.7M | $1.5B | ||
| Q2 24 | $33.9M | $1.5B | ||
| Q1 24 | $36.1M | $1.5B |
负债/权益比DCTHRVSB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 1.07× | — | ||
| Q1 24 | 0.50× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.2M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $7.7M | $-736.0K |
| 自由现金流率自由现金流/营收 | 37.1% | -5.2% |
| 资本支出强度资本支出/营收 | 2.7% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $21.0M | $20.4M |
8季度趋势，按日历期对齐
经营现金流DCTHRVSB
| Q4 25 | $8.2M | $-506.0K | ||
| Q3 25 | $4.8M | $16.8M | ||
| Q2 25 | $7.3M | $-697.0K | ||
| Q1 25 | $2.2M | $8.3M | ||
| Q4 24 | $-1.0M | $2.2M | ||
| Q3 24 | $-3.6M | $764.0K | ||
| Q2 24 | $-4.5M | $5.4M | ||
| Q1 24 | $-9.6M | $12.8M |
自由现金流DCTHRVSB
| Q4 25 | $7.7M | $-736.0K | ||
| Q3 25 | $4.3M | $16.4M | ||
| Q2 25 | $6.9M | $-773.0K | ||
| Q1 25 | $2.1M | $5.6M | ||
| Q4 24 | $-1.2M | $1.9M | ||
| Q3 24 | $-3.9M | $-1.4M | ||
| Q2 24 | $-4.6M | $5.3M | ||
| Q1 24 | $-9.6M | $7.1M |
自由现金流率DCTHRVSB
| Q4 25 | 37.1% | -5.2% | ||
| Q3 25 | 21.0% | 120.1% | ||
| Q2 25 | 28.5% | -5.8% | ||
| Q1 25 | 10.4% | 43.1% | ||
| Q4 24 | -8.2% | 15.0% | ||
| Q3 24 | -34.4% | -11.3% | ||
| Q2 24 | -58.6% | 43.7% | ||
| Q1 24 | -305.7% | 79.0% |
资本支出强度DCTHRVSB
| Q4 25 | 2.7% | 1.6% | ||
| Q3 25 | 2.2% | 2.9% | ||
| Q2 25 | 1.6% | 0.6% | ||
| Q1 25 | 0.7% | 21.0% | ||
| Q4 24 | 1.5% | 2.4% | ||
| Q3 24 | 1.9% | 17.3% | ||
| Q2 24 | 1.3% | 0.9% | ||
| Q1 24 | 0.4% | 62.0% |
现金转化率DCTHRVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | 5.75× | 15.25× | ||
| Q2 25 | 2.70× | -0.57× | ||
| Q1 25 | 2.06× | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | -1.95× | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DCTH
| HEPZATOKIT | $19.1M | 92% |
| CHEMOSAT | $1.7M | 8% |
RVSB
暂无分部数据
